{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:27Z","timestamp":1784557047896,"version":"3.55.0"},"reference-count":35,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence on the efficacy and safety of anticoagulation in preventing stroke and thromboembolic events in people with thyrotoxic atrial fibrillation is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We evaluated the efficacy and safety of anticoagulation in people with thyrotoxic atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study protocol was published in the International Prospective Register of Systematic Reviews (registration no. CRD42020222782). Four databases and two systematic review registers were searched through 25 November 2020 for interventional and observational studies comparing anticoagulation therapy with active comparators, placebo, or no treatment in people with thyrotoxic atrial fibrillation. Random-effects meta-analysis and sensitivity analysis were performed. Quality of evidence was described using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the study, 23,145 records were retrieved. One randomized controlled trial and eight cohort studies were ultimately included. Effect estimates on the efficacy and safety of anticoagulation were extracted. Meta-analysis using the inverse variance and random-effects methods was conducted on four cohort studies with 3443 participants and 277 events. Anticoagulation in people with thyrotoxic atrial fibrillation reduced the risk of ischemic stroke and systemic thromboembolism by 3% (95% CI: 1\u20136%). Warfarin may prevent ischemic stroke in people with thyrotoxic atrial fibrillation if the CHA2DS2-VASc score exceeds 1 and when atrial fibrillation persists beyond 7 days. Direct oral anticoagulants may be associated with fewer bleeding events than warfarin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anticoagulation prevents ischemic stroke and systemic thromboembolism in people with thyrotoxic atrial fibrillation. Direct oral anticoagulants may be associated with fewer bleeding events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-22-0166","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T06:54:45Z","timestamp":1651820085000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of anticoagulation in thyrotoxic atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1530","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-6238","authenticated-orcid":true,"given":"Eng-Loon","family":"Tng","sequence":"first","affiliation":[{"name":"Department of Medicine, Level 8, Tower A, Ng Teng Fong General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Sian","family":"Tiong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Level 8, Tower A, Ng Teng Fong General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aye Thida","family":"Aung","sequence":"additional","affiliation":[{"name":"Department of Medicine, Level 8, Tower A, Ng Teng Fong General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Ya Yuan","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Medicine, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhemin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"American Heart Journal","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1067\/mhj.2001.119370","article-title":"Subclinical hyperthyroidism as a risk factor for atrial fibrillation","volume":"142","author":"Auer","year":"2001","unstructured":"Auer JScheibner PMische TLangsteger WEber OEber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American Heart Journal2001142838\u2013842. (https:\/\/doi.org\/10.1067\/mhj.2001.119370)1168517210.1067\/mhj.2001.119370"},{"key":"bib2","series-title":"Archives of Internal Medicine","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/archinte.164.15.1675","article-title":"Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study","volume":"164","author":"Frost","year":"2004","unstructured":"Frost LVestergaard PMosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Archives of Internal Medicine20041641675\u20131678. (https:\/\/doi.org\/10.1001\/archinte.164.15.1675)10.1001\/archinte.164.15.1675"},{"key":"bib3","series-title":"Journal of the American College of Cardiology","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jacc.2006.08.042","article-title":"Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study","volume":"49","author":"Osman","year":"2007","unstructured":"Osman FFranklyn JAHolder RLSheppard MCGammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. Journal of the American College of Cardiology20074971\u201381. (https:\/\/doi.org\/10.1016\/j.jacc.2006.08.042)1720772510.1016\/j.jacc.2006.08.042"},{"key":"bib4","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJM199411103311901","article-title":"Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons","volume":"331","author":"Sawin","year":"1994","unstructured":"Sawin CTGeller AWolf PABelanger AJBaker EBacharach PWilson PWBenjamin EJD\u2019Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New England Journal of Medicine19943311249\u20131252. (https:\/\/doi.org\/10.1056\/NEJM199411103311901)793568110.1056\/NEJM199411103311901"},{"key":"bib5","series-title":"Thyroid","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/105072502760143863","article-title":"Hyperthyroidism and the management of atrial fibrillation","volume":"12","author":"Shimizu","year":"2002","unstructured":"Shimizu TKoide SNoh JYSugino KIto KNakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid200212489\u2013493. (https:\/\/doi.org\/10.1089\/105072502760143863)1216511110.1089\/105072502760143863"},{"key":"bib6","series-title":"Journal of Thyroid Research","first-page":"4259183","article-title":"Thyrotoxic atrial fibrillation: factors associated with persistence and risk of ischemic stroke","volume":"2017","author":"Wong","year":"2017","unstructured":"Wong CLTam HVFok CVLam PEFung LM. Thyrotoxic atrial fibrillation: factors associated with persistence and risk of ischemic stroke. Journal of Thyroid Research201720174259183. (https:\/\/doi.org\/10.1155\/2017\/4259183)29379659"},{"key":"bib7","series-title":"Cardiology","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000356954","article-title":"Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation","volume":"127","author":"Chen","year":"2014","unstructured":"Chen QYan YZhang LCheng KLiu YZhu W. Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation. Cardiology2014127176\u2013182. (https:\/\/doi.org\/10.1159\/000356954)2443454410.1159\/000356954"},{"key":"bib8","series-title":"Thrombosis and Haemostasis","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1160\/TH12-07-0496","article-title":"The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis","volume":"108","author":"Stuijver","year":"2012","unstructured":"Stuijver DJvan Zaane BRomualdi EBrandjes DPGerdes VESquizzato A. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thrombosis and Haemostasis20121081077\u20131088. (https:\/\/doi.org\/10.1160\/TH12-07-0496)2301470810.1160\/TH12-07-0496"},{"key":"bib9","series-title":"Seminars in Thrombosis and Hemostasis","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1055\/s-0029-1222607","article-title":"Thyroid dysfunction and hemostasis: an issue still unresolved","volume":"35","author":"Franchini","year":"2009","unstructured":"Franchini MMontagnana MManzato FVescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Seminars in Thrombosis and Hemostasis200935288\u2013294. (https:\/\/doi.org\/10.1055\/s-0029-1222607)1945240410.1055\/s-0029-1222607"},{"key":"bib10","series-title":"European Heart Journal","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","unstructured":"Kirchhof PBenussi SKotecha DAhlsson AAtar DCasadei BCastella MDiener HCHeidbuchel HHendriks J2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016372893\u20132962. (https:\/\/doi.org\/10.1093\/eurheartj\/ehw210)2756740810.1093\/eurheartj\/ehw210"},{"key":"bib11","series-title":"Cardiology","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000357613","article-title":"Hyperthyroid atrial fibrillation: does it matter for stroke risk?","volume":"128","author":"Poulin","year":"2014","unstructured":"Poulin MFDoukky R. Hyperthyroid atrial fibrillation: does it matter for stroke risk?Cardiology201412851\u201353. (https:\/\/doi.org\/10.1159\/000357613)2452604210.1159\/000357613"},{"key":"bib12","series-title":"Clinical Cardiology","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/clc.22427","article-title":"Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation","volume":"38","author":"Chan","year":"2015","unstructured":"Chan PHHai JYeung CYLip GYLam KSTse HFSiu CW. Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation. Clinical Cardiology201538476\u2013482. (https:\/\/doi.org\/10.1002\/clc.22427)2624868110.1002\/clc.22427"},{"key":"bib13","series-title":"Heart Rhythm","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.hrthm.2008.10.023","article-title":"Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism","volume":"6","author":"Siu","year":"2009","unstructured":"Siu CWPong VZhang XChan YHJim MHLiu SYiu KHKung AWLau CPTse HF. Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm20096169\u2013173. (https:\/\/doi.org\/10.1016\/j.hrthm.2008.10.023)1918790510.1016\/j.hrthm.2008.10.023"},{"key":"bib14","series-title":"American Journal of Cardiology","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.amjcard.2019.07.046","article-title":"Characteristics and outcomes of atrial fibrillation in patients with thyroid disease (from the Aristotle Trial)","volume":"124","author":"Goldstein","year":"2019","unstructured":"Goldstein SAGreen JHuber KWojdyla DMLopes RDAlexander JHVinereanu DWallentin LGranger CBAl-Khatib SM. Characteristics and outcomes of atrial fibrillation in patients with thyroid disease (from the Aristotle Trial). American Journal of Cardiology20191241406\u20131412. (https:\/\/doi.org\/10.1016\/j.amjcard.2019.07.046)3147432810.1016\/j.amjcard.2019.07.046"},{"key":"bib15","series-title":"BMJ Open","article-title":"Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant-Danish nationwide cohort study","volume":"9","author":"Gundlund","year":"2019","unstructured":"Gundlund AK\u00fcmler TBonde ANButt JHGislason GHTorp-Pedersen CK\u00f8ber LOlesen JBFosb\u00f8l EL. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant-Danish nationwide cohort study. BMJ Open20199 e028468. (https:\/\/doi.org\/10.1136\/bmjopen-2018-028468)31542739"},{"key":"bib16","series-title":"BMJ","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","unstructured":"Sterne JACSavovi\u0107 JPage MJElbers RGBlencowe NSBoutron ICates CJCheng HYCorbett MSEldridge SMRoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019366 l4898. (https:\/\/doi.org\/10.1136\/bmj.l4898)31462531"},{"key":"bib17","series-title":"BMJ","article-title":"Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","unstructured":"Sterne JAHern\u00e1n MAReeves BCSavovi\u0107 JBerkman NDViswanathan MHenry DAltman DGAnsari MTBoutron IRobins-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016355 i4919. (https:\/\/doi.org\/10.1136\/bmj.i4919)27733354"},{"key":"bib18","series-title":"Research Synthesis Methods","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","unstructured":"McGuinness LAHiggins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods20211255\u201361. (https:\/\/doi.org\/10.1002\/jrsm.1411)10.1002\/jrsm.1411"},{"key":"bib19","series-title":"Review Manager (RevMan) [Computer Program]. Version 5.4","year":"2020","unstructured":"The Cochrane Collaboration (ed.). Review Manager (RevMan) [Computer Program]. Version 5.4. The Cochrane Collaboration, 2020."},{"key":"bib20","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"dgaa050","article-title":"Direct oral anticoagulants in atrial fibrillation patients with concomitant hyperthyroidism","volume":"105","author":"Chan","year":"2020","unstructured":"Chan YHWu LSSee LCLiu JRChang SHChao TFYeh YHKuo CTLee HFLip GYH. Direct oral anticoagulants in atrial fibrillation patients with concomitant hyperthyroidism. Journal of Clinical Endocrinology and Metabolism2020105dgaa050. (https:\/\/doi.org\/10.1210\/clinem\/dgaa050)32009154"},{"key":"bib21","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/cen.14061","article-title":"Risk of ischaemic stroke in thyrotoxic atrial fibrillation","volume":"91","author":"Chen","year":"2019","unstructured":"Chen ZCWu NCChang CLHo CHLiao CTChiang CYChang WT. Risk of ischaemic stroke in thyrotoxic atrial fibrillation. Clinical Endocrinology201991561\u2013570. (https:\/\/doi.org\/10.1111\/cen.14061)3130125210.1111\/cen.14061"},{"key":"bib22","series-title":"Clinical Research in Cardiology","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00392-016-1040-7","article-title":"Prognosis in patients with atrial fibrillation and a presumed \u2018temporary cause\u2019 in a community-based cohort study","volume":"106","author":"Fauchier","year":"2017","unstructured":"Fauchier LClementy NBisson AStamboul KIvanes FAngoulvant DBabuty DLip GY. Prognosis in patients with atrial fibrillation and a presumed \u2018temporary cause\u2019 in a community-based cohort study. Clinical Research in Cardiology2017106202\u2013210. (https:\/\/doi.org\/10.1007\/s00392-016-1040-7)10.1007\/s00392-016-1040-7"},{"key":"bib23","series-title":"Archives of Internal Medicine","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archinte.1981.00340090087019","article-title":"Arterial embolism in thyrotoxicosis with atrial fibrillation","volume":"141","author":"Bar-Sela","year":"1981","unstructured":"Bar-Sela SEhrenfeld MEliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Archives of Internal Medicine19811411191\u20131192. (https:\/\/doi.org\/10.1001\/archinte.1981.00340090087019)725937910.1001\/archinte.1981.00340090087019"},{"key":"bib24","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/01.STR.19.1.15","article-title":"Stroke in thyrotoxicosis with atrial fibrillation","volume":"19","author":"Petersen","year":"1988","unstructured":"Petersen PHansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke19881915\u201318. (https:\/\/doi.org\/10.1161\/01.str.19.1.15)333689810.1161\/01.STR.19.1.15"},{"key":"bib25","series-title":"BMJ","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/bmj.2.6088.688","article-title":"Arterial embolism in thyrotoxicosis with atrial fibrillation","volume":"2","author":"Staffurth","year":"1977","unstructured":"Staffurth JSGibberd MCFui SN. Arterial embolism in thyrotoxicosis with atrial fibrillation. BMJ19772688\u2013690. (https:\/\/doi.org\/10.1136\/bmj.2.6088.688)90205510.1136\/bmj.2.6088.688"},{"key":"bib26","series-title":"Medical Journal of Australia","doi-asserted-by":"publisher","first-page":"630","DOI":"10.5694\/j.1326-5377.1979.tb119428.x","article-title":"Embolism in thyrotoxic atrial fibrillation","volume":"1","author":"Yuen","year":"1979","unstructured":"Yuen RWGutteridge DHThompson PLRobinson JS. Embolism in thyrotoxic atrial fibrillation. Medical Journal of Australia19791630\u2013631. (https:\/\/doi.org\/10.5694\/j.1326-5377.1979.tb119428.x)49202110.5694\/j.1326-5377.1979.tb119428.x"},{"issue":"(Supplement 1)","key":"bib27","series-title":"Value in Health","first-page":"S56","article-title":"Comparative effectiveness of edoxaban and warfarin in prevention of stroke and systemic embolism in non-valvular atrial fibrillation using observational healthcare data","volume":"21","year":"2018","unstructured":"Zhou L, Zhang R, Chakraborty P, Farooq F & Alford SH. Comparative effectiveness of edoxaban and warfarin in prevention of stroke and systemic embolism in non-valvular atrial fibrillation using observational healthcare data. Value in Health201821(Supplement 1)S56."},{"key":"bib28","series-title":"European Heart Journal","first-page":"1309","article-title":"Effectiveness and safety of direct anticoagulants versus vitamin K antagonists in octogenarians patients with atrial fibrillation in a \u2018real world\u2019 nationwide registry","volume":"39","author":"Ruiz","year":"2018","unstructured":"Ruiz Ortiz MEsteve-Pastor MARanaMiguez PMarin FMartinez-Selles MRoldan IMuniz J Cequier A Bertomeu VAnguita MEffectiveness and safety of direct anticoagulants versus vitamin K antagonists in octogenarians patients with atrial fibrillation in a \u2018real world\u2019 nationwide registry. European Heart Journal2018391309. (https:\/\/doi.org\/10.1093\/eurheartj\/ehy566.P6284)"},{"key":"bib29","series-title":"Archives of Internal Medicine","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/archinte.159.12.1322","article-title":"Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation","volume":"159","author":"Gull\u00f8v","year":"1999","unstructured":"Gull\u00f8v ALKoefoed BGPetersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation. Archives of Internal Medicine19991591322\u20131328. (https:\/\/doi.org\/10.1001\/archinte.159.12.1322)1038650810.1001\/archinte.159.12.1322"},{"key":"bib30","series-title":"European Heart Journal","first-page":"510","article-title":"Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)","volume":"37","author":"Ridha","year":"2016","unstructured":"Ridha ELacoin LLefevreCDonaldsonRRamagopalanSHalcox JAspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF). European Heart Journal201637510\u2013519."},{"key":"bib31","series-title":"European Heart Journal","article-title":"Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian Nationwide Cohort Study","volume":"40","author":"Rutherford","year":"2019","unstructured":"Rutherford OCWJonassonCJGhanimaWGHalvorsenSHEffectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian Nationwide Cohort Study. European Heart Journal201940 1846. (https:\/\/doi.org\/10.1371\/journal.pone.0221500)"},{"key":"bib32","series-title":"Archives of Internal Medicine","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1001\/archinte.1996.00440150095011","article-title":"Warfarin for atrial fibrillation. The patient\u2019s perspective","volume":"156","author":"Man-Son-Hing","year":"1996","unstructured":"Man-Son-Hing MLaupacis AO\u2019Connor AWells GLemelin JWood WDermer M. Warfarin for atrial fibrillation. The patient\u2019s perspective. Archives of Internal Medicine19961561841\u20131848. (https:\/\/doi.org\/10.1001\/archinte.1996.00440150095011)879007910.1001\/archinte.1996.00440150095011"},{"key":"bib33","series-title":"BMJ","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/bmj.318.7194.1324","article-title":"Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation","volume":"318","author":"Howitt","year":"1999","unstructured":"Howitt AArmstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ19993181324\u20131327. (https:\/\/doi.org\/10.1136\/bmj.318.7194.1324)1032382010.1136\/bmj.318.7194.1324"},{"key":"bib34","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/STROKEAHA.115.012609","article-title":"Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis","volume":"47","author":"Joundi","year":"2016","unstructured":"Joundi RACipriano LESposato LASaposnik G & Stroke Outcomes Research Working Group. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke2016471364\u20131367. (https:\/\/doi.org\/10.1161\/STROKEAHA.115.012609)2702663010.1161\/STROKEAHA.115.012609"},{"key":"bib35","series-title":"Vasa: Zeitschrift Fur Gefasskrankheiten","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1024\/0301-1526\/a000746","article-title":"Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation \u2013 a network meta-analysis of real-world data","volume":"48","author":"Hirschl","year":"2019","unstructured":"Hirschl MKundi M. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation \u2013 a network meta-analysis of real-world data. Vasa: Zeitschrift Fur Gefasskrankheiten201948134\u2013147. (https:\/\/doi.org\/10.1024\/0301-1526\/a000746)3037641610.1024\/0301-1526\/a000746"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/11\/5\/EC-22-0166.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/5\/EC-22-0166.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/5\/EC-22-0166.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:45:38Z","timestamp":1784555138000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":35,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/ec-22-0166","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}